Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes.
Hast
R
R
Department of Medicine, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Eriksson
M
M
Jakovleva
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D016207:Cytokines / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D003561:Cytarabine; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013866:Thioguanine; D003630:Daunorubicin